Drug development is a costly and uncertain process. How is AI changing that?

As a part of HUBweek in Boston, STAT’s Casey Ross will lead an engaging discussion with key industry experts about how the ability to process huge stores of data is enabling drug makers to identify the precise mechanisms of disease, build new targeted therapies, and profile the types of patients who would benefit from them. Join us for the conversation on 10/9 by registering now. Coffee and snacks will be provided.